文献速递肾移植慢性肾脏病

唑来膦酸预防肾移植后第一年骨丢失的随机试验

A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.
PubMed 文献 · J Am Soc Nephrol · 2019-01-03

这项开放标签随机试验将34例肾移植前患者分为唑来膦酸组或无治疗组,用DXA、HR-pQCT和骨活检评估32例可评估者移植后12个月骨骼变化。两组移植后骨转换均降低,唑来膦酸未影响该结局;DXA显示两组腰椎和全髋骨密度均增加且唑来膦酸有显著正向效应,但骨活检显示小梁连接性受损且唑来膦酸无获益,HR-pQCT检测到外周骨小梁丢失且唑来膦酸部分减轻。结论认为当前免疫抑制方案不导致中轴骨小梁丢失,唑来膦酸不诱导无动力骨病,高骨折风险且骨量显著低下者应考虑双膦酸盐。

要点

  • 肾移植后两组骨转换均降低,唑来膦酸本身未改变该结局。
  • DXA显示两组腰椎和全髋骨密度增加,唑来膦酸有显著正向效应。
  • 骨活检示小梁连接性受损且唑来膦酸无获益,HR-pQCT示外周骨小梁丢失且唑来膦酸部分减轻。

核心结论

  • 当前免疫抑制方案不导致肾移植后中轴骨小梁骨丢失,唑来膦酸不诱导无动力骨病。
  • 移植受者骨折以外周骨折最常见,高骨折风险且移植时外周骨量显著低下者应考虑双膦酸盐。

研究设计与样本

  • 开放标签随机试验,移植前随机34例患者接受唑来膦酸或无治疗。
  • 用DXA、HR-pQCT和骨活检评估32例可评估者从肾移植到移植后12个月的骨骼变化。

主要发现

  • 两组移植后骨转换均降低,唑来膦酸本身未影响该结局。
  • DXA显示两组腰椎和全髋骨密度均增加,唑来膦酸有显著正向效应。
  • 骨活检显示移植后小梁连接性受损且唑来膦酸无获益。
  • HR-pQCT检测到外周骨架小梁骨丢失,唑来膦酸部分减轻。

临床怎么用

  • 对高骨折风险且移植时外周骨量显著低下的患者,可考虑使用双膦酸盐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bone and mineral disorders commonly affect kidney transplant (KTx) recipients and have been associated with a high risk of fracture. Bisphosphonates may prevent or treat bone loss in such patients, but there is concern that these drugs might induce adynamic bone disease (ABD). METHODS: In an open label, randomized trial to assess the safety and efficacy of zoledronate for preventing bone loss in the first year after kidney transplant, we randomized 34 patients before transplant to receive zoledronate or no treatment. We used dual-energy x-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HR-pQCT), and bone biopsies to evaluate changes in bone in the 32 evaluable participants between the time of KTx and 12 months post-transplant. RESULTS: Both groups of patients experienced decreased bone turnover after KTx, but zoledronate itself did not affect this outcome. Unlike previous studies, DXA showed no post-transplant bone loss in either group; we instead observed an increase of bone mineral density in both lumbar spine and total hip sites, with a significant positive effect of zoledronate. However, bone biopsies showed post-transplant impairment of trabecular connectivity (and no benefit from zoledronate); HR-pQCT detected trabecular bone loss at the peripheral skeleton, which zoledronate partially attenuated. CONCLUSIONS: Current immunosuppressive regimens do not contribute to post-transplant central skeleton trabecular bone loss, and zoledronate does not induce ABD. Because fractures in transplant recipients are most commonly peripheral fractures, clinicians should consider bisphosphonate use in patients at high fracture risk who have evidence of significantly low bone mass at these sites at the time of KTx.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Marques IDB, Araújo MJCLN, Graciolli FG, et al. A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation. J Am Soc Nephrol. 2019. PMID: 30606784. doi:10.1681/ASN.2018060656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。